MGNX Deadline: Rosen Law Firm Urges MacroGenics, Inc. (NASDAQ: MGNX) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024. MacroGenics describes itself as a “biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.”

For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.

The Allegations: Rosen Law Firm is Investigating the Allegations that MacroGenics, Inc. (NASDAQ: MGNX) Misled Investors Regarding its Business Operations.

According to the lawsuit, throughout the Class Period, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts related to early interim safety data results from the TAMARACK Phase 2 study. The claims arise on May 9, 2024, when MacroGenics presented interim updated safety and efficacy data for its cancer treatment study TAMARACK. When the true details entered the market, the lawsuit claims that investors suffered damages.

What Now: You may be eligible to participate in the class action against MacroGenics, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by September 24, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Rosen Law: Some law firms issuing releases about this matter do not actually litigate securities class actions; Rosen Law Firm does. A recognized leader in shareholder rights litigation, the attorneys and staff of Rosen Law Firm have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing. Since our inception, we have obtained over $1 billion for shareholders.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240917629242/en/